← All indications
Cellulitis
An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.
Subtype terms (2)
More specific conditions that are subtypes of Cellulitis in the MeSH hierarchy.
- Ludwig's Angina
2 drugs approved
- Orbital Cellulitis
1 drug approved
Drugs by status
Approved for this indication (4)
Phase 4 trials (7)
Phase 3 trials (10)
Phase 2 trials (4)
Organizations
Organization Involved with Phase 4 Indications (28)
- Forest Laboratories
- Novartis
- Allergan
- Cubist
- GlaxoSmithKline
- ZonMw: The Netherlands Organisation for Health Research and Development
- Public Health England
- Ascension Health
- Henry Ford Health System
- Hospital Universitario Evangelico de Curitiba
- Johns Hopkins University
- Mater Misericordiae University Hospital
- St. John Providence Health System
- University of Nottingham
- University of Bristol
- Wayne State University
- Royal College of Surgeons, Ireland
- University of Cincinnati
- University of Amsterdam
- Mercy University
- Joseph M. Still Research Foundation, Inc.
- Washington University in St. Louis
- Action Medical Research
- Thrasher Research Fund
- Health Research Board, Ireland
- UK Dermatology Clinical Trials Network
- National University of Ireland
- Michigan Ear Institute
Organization Involved with Phase 3 Indications (14)
- Durata
- The Medicines Company
- Theravance
- Basilea Pharmaceutica
- Stiefel Laboratories
- AstraZeneca
- Duke University
- Kaiser Permanente
- Los Angeles Biomedical Research Institute
- Universidade Estadual de Londrina
- University of British Columbia
- University of California, Los Angeles
- Johnson and Johnson
- Universidade Norte do Paraná
Organization Involved with Phase 2 Indications (17)
- Targanta
- Bayer
- CrystalGenomics, Inc.
- Lytix Biopharma AS
- Protez Pharmaceuticals
- Affinium Pharmaceuticals, Ltd
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Melinta Therapeutics
- Trius Therapeutics
- Pennsylvania State University
- St. George Albert Clinic Zeged University Hospital
- Interior Health, Canada
- Humboldt University
- Government of Canada
- Canadian Society of Hospital Pharmacists
- Innovation Pharmaceuticals
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (18)
- Sonescence, Inc.
- United States Army
- Uniformed Services University of the Health Sciences
- United States Navy
- Rockefeller University
- CES University
- Cancer Research Network
- Clinical Directors Network
- Harvard University
- Hospital General de Niños Pedro de Elizalde
- Sutter Health
- University of Melbourne
- University of California, San Francisco
- Sonoma West Medical Center
- Murdoch University
- Yeshiva University
- Centers for Disease Control and Prevention (CDC)
- Becton Dickinson